Enliven Therapeutics Inc
ELVN
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.04B
Close$
$1.74
95.8% downside
Current Fair Value
95.8% downsideOvervalued by 95.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.04 Billion |
|---|---|
| Enterprise Value | $2.91 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.83 |
| Beta | 0.25 |
| Outstanding Shares | 66,171,581 |
Return
| Return on Equity | -11.83% |
|---|---|
| Return on Assets | -11.64% |
| Return on Invested Capital | -12.81% |
Valuation & Multiples
| P/E Ratio | -25.32 |
|---|---|
| PEG | -89.71 |
| Price to Sales | - |
| Price to Book Ratio | 3.19 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -25.35 |
| Enterprise Value to Net Income | -28 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.39
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.45
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 64.84% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.91%▼ 119.97% |
|---|---|
| Total Invested | $57.81M▼ 98.58% |
| Investors Holding | 8▼ 214.00% |
ESG Score
No data
About Enliven Therapeutics Inc
41 employees